Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 crawled date : 2021 - 06 - 28 save search
CEL-SCI’s Multikine® Immunotherapy Produces Significant 14.1% 5-Year Survival Benefit (62.7% Vs 48.6%) in the Group Receiving Surgery Plus Radiotherapy in a Landmark Head and Neck Cancer Phase 3 Study
Published: 2021-06-28 (Crawled : 16:00) - biospace.com/
CVM | $1.56 4.0% 0.0% 230K
|
Health Technology
|
| O: 7.26%
H: 1.41%
C: -49.11%
immunotherapy therapy cancer phase 3 iot cel
Antares Pharma Announces Partner Idorsia Initiates the Phase 3 Study With Selatogrel for Acute Myocardial Infarction
Published: 2021-06-28 (Crawled : 14:00) - biospace.com/
ATRS | $5.59 0.0%
|
Health Technology
|
| O: 0.23%
H: 1.84%
C: -1.61%
phase 3 pharma
Crinetics Announces Dosing of First Patient in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
Published: 2021-06-28 (Crawled : 13:15) - crinetics.com
CRNX | $42.98 -0.07% -0.07% 620K
|
Health Technology
|
| O: 1.53%
H: 1.41%
C: -1.2%
treatment phase 3
Daré Bioscience Announces Positive Phase 1 Results for DARE-HRT1
Published: 2021-06-28 (Crawled : 12:15) - globenewswire.com
DARE | $0.2838 -3.83% -3.98% 550K
|
Health Technology
|
| O: 0.0%
H: 1.78%
C: -0.59%
phase 1 positive results phase 2 phase 3 bioscience
Crinetics Pharmaceuticals Announces Dosing of First Patient in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
Published: 2021-06-28 (Crawled : 12:00) - biospace.com/
CRNX | $42.98 -0.07% -0.07% 620K
|
Health Technology
|
| O: 1.53%
H: 1.41%
C: -1.2%
treatment phase 3
Galera Announces Completion of Enrollment in Pivotal 455-Patient Phase 3 Trial of Avasopasem for Severe Oral Mucositis
Published: 2021-06-28 (Crawled : 12:00) - biospace.com/
GRTX | $0.1833 -1.45% -1.47% 800K
|
Health Technology
|
| O: 2.73%
H: 3.74%
C: 0.59%
phase 3 trial oral mucositis enroll avasopasem
IDEAYA Announces IDE397 Phase 1 Clinical Pharmacodynamic Data and Phase 2 Initiation of Darovasertib and Crizotinib Combination
Published: 2021-06-28 (Crawled : 11:00) - biospace.com/
IDYA | $37.1 -1.38% -1.4% 730K
|
Health Technology
|
| O: 0.46%
H: 0.65%
C: -1.62%
phase 2 phase 1 phase 3
Exelixis and Ipsen Announce Cabozantinib in Combination with an Immune Checkpoint Inhibitor Significantly Improved Progression-Free Survival in Phase 3 COSMIC-312 Pivotal Trial in Patients with Previously Untreated Advanced Liver Cancer
Published: 2021-06-28 (Crawled : 09:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.24%
H: 0.03%
C: -0.47%
EXEL | $22.51 0.09% 0.09% 2.3M
|
Health Technology
|
| O: -13.27%
H: 2.16%
C: -11.28%
cancer phase 3 liver trial
Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction
Published: 2021-06-28 (Crawled : 06:00) - globenewswire.com
ATRS | $5.59 0.0%
|
Health Technology
|
| O: 0.23%
H: 1.84%
C: -1.61%
treatment phase 3
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.